期刊
JOURNAL OF EXPERIMENTAL MEDICINE
卷 217, 期 10, 页码 -出版社
ROCKEFELLER UNIV PRESS
DOI: 10.1084/jem.20181551
关键词
-
资金
- CSHL Cancer Center [P30-CA045508]
- Department of Defense [W81XWH-14-1-0078]
- Charles and Marie Robertson Foundation
- Lustgarten Foundation
- National Cancer Institute
- Cedar Hill Foundation
- Rita Allen Foundation
- V Foundation for Cancer Research
- Starr Centennial Scholarship from the Watson School of Biological Sciences
- Simons Foundation
- State of New York [C150158]
C-C chemokine receptor type 2 (CCR2) is expressed on monocytes and facilitates their recruitment to tumors. Though breast cancer cells also express CCR2, its functions in these cells are unclear. We found that Ccr2 deletion in cancer cells led to reduced tumor growth and approximately twofold longer survival in an orthotopic, isograft breast cancer mouse model. Deletion of Ccr2 in cancer cells resulted in multiple alterations associated with better immune control: increased infiltration and activation of cytotoxic T lymphocytes (CTLs) and CD103(+). cross-presenting dendritic cells (DCs), as well as up-regulation of MHC class I and down-regulation of checkpoint regulator PD-L1 on the cancer cells. Pharmacological or genetic targeting of CCR2 increased cancer cell sensitivity to CTLs and enabled the cancer cells to induce DC maturation toward the CD103(+). subtype. Consistently, Ccr2(-/-) cancer cells did not induce immune suppression in Batf(3/-) mice lacking CD103(+) DCs. Our results establish that CCR2 signaling in cancer cells can orchestrate suppression of the immune response.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据